People In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA's Goodman named acting chief medical officer: Jesse Goodman is serving as FDA's acting chief medical officer as the agency management realigns to prepare for the new administration's topside leadership team. Goodman, director of the Center for Biologics Evaluation & Research since 2002, was detailed to the CMO post the week of March 9, FDA said. CBER Deputy Director Karen Midthun is now running the biologics center. A virologist by training, Goodman joined FDA in 1998 to direct the interagency task force on antimicrobial resistance. He later moved into CBER, where his work on bioterrorism preparedness brought him into the same orbit as FDA Commissioner-nominee Margaret Hamburg. The two served on several Institute of Medicine panels focused on microbial threats and bioterrorism preparedness in 2002 and 2003. Goodman was also selected as FDA's lone representative on the Federal Coordinating Committee on Comparative Effectiveness Research, appointed by the Department of Health and Human Services March 19
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.